Page 31 - Deleware Medical Journal - September/October 2019

ORIGINAL RESEARCH
Table 1: Clinical Characteristics of all Patients
Median Survival
344 days (range 1 – 2169)
Characteristic
No. of patients n (%) 134 (%)
Median Age
66.7 (range 32-94)
Race
White
116 (86)
Black
14 (10)
Hispanic
1 (1)
Asian
1 (1)
Unknown
2 (2)
Primary Site
Frontal Lobe
38 (28)
Temporal Lobe
35 (26)
Parietal Lobe
17 (13)
Occipital Lobe
6 (4)
Thalamus Lobe
4 (3)
Brain, Overlapping Lesion
13 (10)
Brain, NOS
21 (16)
First Surgical Intervention
Biopsy Only
19 (14)
Gross Tumor Resection
101 (75)
Unknown
8 (6)
Neither (Early Hospice or Death)
6 (5)
First Intervention post-operatively
No Intervention
36 (27)
Radiotherapy or Chemo Alone
5 (4)
Chemoradiation
75 (56)
Treatment Elsewhere; No Data Available
18 (13)
The primary outcome for this study was survival time in days.
RESULTS
in the analysis. The demographic and clinical characteristics of all patients are shown in Table 1. The median age was 67 years (range 32-94). Twenty-eight percent of tumors were frontal lobe,
26% were temporal lobe, and 13% were parietal lobe. There were 14% of patients who underwent biopsy alone without any further surgical intervention. There were 75% of patients who underwent gross tumor resection with either partial or maximal debulking. Only 6% either had surgery done elsewhere before receiving additional treatments at our institution or went elsewhere after initial diagnosis. There were 5% of patients who did not undergo any surgical intervention or biopsy after initial brain imaging due to the severity of presenting illness, death, or early hospice referral. There were 27% of patients who did not receive any combination of chemoradiation, 56%
of patients received chemoradiation,
and less than 5% received radiation or temozolomide alone. There were 13% who went elsewhere to complete the treatment plan and this data was not available. Median survival was 344 days (range 1-2,169 days) as shown in Table 1.
Subgroup analysis was completed as described below. Of all 134 people included in this study, 19 patients underwent biopsy alone (14%) as their only primary surgical intervention and 101 underwent gross tumor resection (either partial or total, 75%). In regard to survival days, the median survival days for the patients who underwent biopsy alone was 83 days and 414 days for gross tumor resection. Of the 134 subjects, there were 72 men (54%) and 62 women (46%); the median survival days for men
were 319 days and 371 days for women. There were 79 patients (59%) who were 65 years of age or older. The overall median survival in days was 213 days for those 65 and older compared to 530 days for those 55 patients (41%) who were under the age of 65.
black. The overall median survival for the 116 white patients was 356 days compared to 285 days for black patients.
DISCUSSION
This study details the demographics of
all cases of GBM treated from January 1, 2011, to December 31, 2015, at Christiana Care Health System. To our knowledge,
this is the only study completed in the
state of Delaware to document both patient characteristics and overall survival of GBM. Several factors play a role in the median overall survival of patients with glioblastoma, some of which are highlighted
Del Med J | September/October 2019 | Vol. 91 | No. 5
223